On July 31, 2020, Rexahn Pharmaceuticals, Inc. (the "Company") reported that entered into a Warrant Exchange Agreement (the "Agreement") with Armistice Capital Master Fund Ltd. ("Armistice") (Filing, 8-K, Rexahn, JUL 31, 2020, View Source [SID1234564590]). The Company previously issued to Armistice (a) a warrant to purchase 160,257 shares (on a post-reverse stock split basis) of its common stock, par value $.0001 per share (the "Common Stock") pursuant to the offering described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on October 19, 2018 (the "2018 Warrant"), and (b) a warrant to purchase 208,334 shares (on a post-reverse stock split basis) of Common Stock pursuant to the offering described in the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2019 (the "2019 Warrant" and together with the 2018 Warrant, the "Warrants"). Pursuant to the Agreement, on August 3, 2020, the Company is issuing to Armistice an aggregate of 215,000 shares of Common Stock in exchange for the surrender and cancellation of the Warrants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!